Therefore, developing small molecule inhibitors targeting CARM1 enzymatic activity or peptides mimicking sequence motifs in CARM1 methylation sites will provide an additional therapeutic adjunct for ERα-positive and endocrine therapy-resistance breast cancers. This evidence concerns the gene ESR1 and breast cancer.